A Targeted Oncology Biotech

A Targeted Oncology Biotech. May, 2023.

[Audio] Our focus is on the DNA damage repair pathway, and Onco genes. Our portfolio includes pre-clinical programs for a first-in-class R A D 51-Braca disruptor, and a best-in-class S O S 1 inhibitor. In addition, we have earlier stage programs targeting P A R G, P K M Y T 1 and KIF18 Alpha. Our business Model is to license our pre-clinical stage assets, or to partner earlier stage programs in integrated drug discovery partnerships.

[Audio] Our leadership has experience of generating over 25 programs currently in different stages of clinical development. The Founder and the CSO have led companies such as Aurigene and Rhizen in the past. The Medicinal Chemistry and Biology leadership has over 15 years of drug discovery expertise focused on oncology. The company is advised by senior industry professionals, drawn from companies such as Novo Nordisk, Onyx and Sanofi..

[Audio] Our first-in-class RAD51 program, in the DDR pathway, addresses difficult to treat solid tumors with high replication stress. The target population is similar to those addressed by PARP, ATR, ATM or WEE 1 inhibitors. Pre-clinically, Satya's R A D 51 compound appears better tolerated, and more efficacious compared to other DDR pathway targets. The S O S 1 compound of Satya demonstrates better Pharmacodynamic read outs compared to competitor compounds, and is targeted to treat Wild Type RAS driven tumors, as well as EGFR and mutant RAS driven tumors. Both these programs would need about 6 to 9 months for an I N D filing In summary, Satya, with its portfolio of programs in the DNA damage repair pathway, and S O S 1, is a targeted oncology biotech that seeks to license its pre-clinical stage assets, or partner earlier stage programs in integrated drug discovery partnerships.

Thank You. murthycsn@satyarx.com.